Munich, 1 September 2009 – The Japanese pharmaceutical group DAIICHI SANKYO is launching its market-expansion push into Eastern Europe by licensing the osteoporosis medication EVISTA® to Terapia Ranbaxy. This is the first time in Europe that the Group is leveraging the synergies generated by the Hybrid Business Model with Ranbaxy. “Ranbaxy has a strong presence in Eastern European markets and in Russia as well. We intend to take increasing advantage of this market access for our patented medications,” said Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE.

Said, Mr. Mahendra Bharadwaj, Chief Executive Officer, Terapia Ranbaxy, “We are delighted to partner with DAIICHI SANKYO EUROPE for the launch of EVISTA® in Romania. Terapia Ranbaxy is currently the No. 1 generic company in Romania with a large and experienced field force that will spearhead the launch of EVISTA®. We look forward to enduring synergies and hope to launch many new products with DAIICHI SANKYO EUROPE in the future".

With a population of 22 million people, Romania is Eastern Europe’s second-biggest market after Poland. Annual turnover in the Romanian pharmaceutical market totals about $2.5 billion, and the market is growing at around 20 per cent a year, in local currency terms. Terapia Ranbaxy is one of the seven largest pharmaceutical companies in Romania.

DAIICHI SANKYO also plans to expand into other Eastern European countries through Ranbaxy. That market expansion is designed to help the Group to achieve its strategic objectives. DAIICHI SANKYO is striving for a turnover in Europe of €1 billion till 2011. By 2015, DAIICHI SANKYO intends to be one of the leading pharmaceutical companies here as well.

CONTACT
Thorsten Schüller
Media Relations
Phone +49(0)89/78 08-657
thorsten.schueller@daiichi-sankyo.eu

Olaf Lamberz

Corporate Communications

Phone +49(0)89/78 08-442

olaf.lamberz@daiichi-sankyo.eu

^{Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO EUROPE GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.}